VICHY CONNECT PRO’s Post

If you are attending this year's European Academy of Dermatology & Venereology (EADV) please make sure to stop by our poster presented by Dr. Mark Lebwohl on the Comparative Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis. This Systematic Literature Review and Network Meta-Analysis is a result of our collaborations with esteem colleagues from Sun Pharma and key opinion leaders from academia and provide valuable insights into treatment options for patients with psoriasis. Join us in the session Psoriasis - Part 2 to explore the data! https://lnkd.in/gXeizZqK

April Armstrong, MD, Professor and Chief of Dermatology at UCLA, shares interim results from the TRACE study. Presented at the 2024 European Academy of Dermatology and Venereology Congress in Amsterdam, the study found that the percentage of patients with baseline head and neck atopic dermatitis (AD) who had an Investigator’s Global Assessment score of 0 (clear) or 1 (almost clear) (IGA 0/1) increased from 1.4% at baseline to 33.6% at three months, 48.4% at six months, and 57.4% at nine months of treatment with tralokinumab (Adbry/Adtralza, Leo), regardless of previous biologic treatment. https://lnkd.in/d2HZv9Eh

💡 What are some useful clinical pearls for dermatologists? In his portion of the #FallClinical Dermatology conference presentation '20 Tips in 20 Minutes,' Eingun James Song, MD, FAAD, provided several unique insights in his discussion of 4 tips for implementation into clinical practice. HCPLive had the opportunity to interview Dr. Song regarding these clinical pearls and their use among dermatologists. Check out the first segment of his interview and its summary here: https://lnkd.in/eUNyiFmb

Latest living network meta-analysis (NMA) update published in JAMA Dermatology! We are delighted to share the results of our NMA, this time focused on lebrikizumab and how it compares to other systemic treatments for atopic dermatitis. Do check out our open access paper here: https://lnkd.in/gJEW39TY JAMA Dermatol. doi:10.1001/jamadermatol.2024.2192 Carsten Flohr and Aaron Drucker

April Armstrong, MD MPH, Professor and Chief of #Dermatology at the David Geffen School of Medicine at UCLA, shares interim results from the TRACE study. Presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the study found that the percentage of patients with baseline head and neck #atopicdermatitis (AD) who had an Investigator’s Global Assessment score of 0 (clear) or 1 (almost clear) (IGA 0/1) increased from 1.4% at baseline to 33.6% at three months, 48.4% at six months, and 57.4% at nine months of treatment with tralokinumab (Adbry/Adtralza, LEO Pharma), regardless of previous biologic treatment. https://lnkd.in/dYU4HVpw

This #FollowFriday, we wanted to spotlight founder and CEO of Dermatology Research and Education Foundation, Jashin Wu, MD, FAAD. Dr. Wu is also Founding Director of Dermatology Research at Kaiser Permanente. Follow Dr. Wu for more information on the latest research around #psoriasis.

Did you know? Patients with periodontitis are at a much greater risk of developing Alopecia Areata, an autoimmune disease characterized by hair loss, according to a study published in the Journal of the European Academy of Dermatology and Venereology. While the exact link isn't clear, it may be due to the common autoimmune-inflammatory nature of both diseases. Help your patients stay on top of their health to protect their well-being! To learn more about how you can help your patients understand the importance of maintaining a healthy smile, download our free infographics bundle: https://hubs.la/Q02Lgvmx0, and SHARE this post!

Live Webinar – Acne Vulgaris Therapeutic Update: Overview of the 2024 Treatment Guidelines on May 30th.  Over 50 million people in the US have acne, leading to $846 million in medical costs and $398 million in lost productivity. This live webinar will review acne vulgaris and its clinical features along with summarizing the 2024 American Academy of Dermatology Guidelines for this condition. Learn More - https://bit.ly/3JHDto4 FACULTY - Darrell Hulisz, RPh, PharmD

#SCALE2024 Session Spotlight: New Topicals for Hyperpigmentation with Edward (Ted) Lain, MD, MBA In a session at SCALE 2024, Dr. Ted Lain provided a comprehensive update on the latest advancements in topical treatments for hyperpigmentation. 🌟 Dr. Lain, a leading expert in dermatology, shared cutting-edge insights into the efficacy and application of new topical agents, highlighting their role in managing and mitigating various forms of hyperpigmentation. His presentation covered recent research findings, and practical recommendations for integrating these findings into clinical practice. Attendees left with a deeper understanding of how these topicals can enhance patient outcomes and address the challenges of hyperpigmentation. 🧴🔬✨ What did you take away from this session?

James Q. Del Rosso, DO updated! The original tapinarof trial DID include intertriginous psoriasis To learn more about the phase 4 results check out the interview HCPLive